Arthritis News and Research

Latest Arthritis News and Research

'Prehabilitation' exercise program can improve strength, functional ability before knee replacement surgery

A comprehensive "prehabilitation" exercise program for patients with severe knee arthritis can improve strength and functional ability before knee replacement surgery, reports a study in the February issue of The Journal of Strength and Conditioning Research, official research journal of the National Strength and Conditioning Association.

2 Mar 2011

Leptin receptor antagonist peptide demonstrates efficacy against triple negative breast cancer

A new peptide developed by researchers in Temple University's College of Science and Technology has demonstrated efficacy against triple negative breast cancer.

1 Mar 2011

Daiichi Sankyo enters merger agreement to acquire Plexxikon

Plexxikon Inc. today announced it has entered into a merger agreement with Daiichi Sankyo Company, Limited, a Japan-based global pharmaceutical company.

28 Feb 2011

Regeneron's ARCALYST meets primary, secondary endpoints in second Phase 3 gout flare study

Regeneron Pharmaceuticals, Inc. announced that in a second Phase 3 study (PRE-SURGE 2) in gout patients initiating allopurinol therapy, ARCALYST (rilonacept) met the primary and all secondary study endpoints. The primary endpoint was the number of gout flares per patient over the 16-week treatment period.

28 Feb 2011

Exactech fourth quarter total revenue increases 7% to $51.8 million

Exactech, Inc., a developer and producer of bone and joint restoration products for hip, knee, extremities, spine and biologic materials, announced today that revenue for 2010 increased 7% to $190.5 million from $177.3 million in 2009. Diluted earnings per share for the year was $0.80 based on net income of $10.5 million.

28 Feb 2011

SQI Diagnostics first quarter net loss increases to $2,255,000

SQI Diagnostics Inc., a medical systems automation company focused on evolving laboratory-based autoimmune biomarker testing, today announced its financial and operational results for the first quarter ended December 31, 2010.

28 Feb 2011

New horse stem cell discovery aids in preclinical model development for human degenerative diseases

In a world first, pluripotent stem cells have been generated from horses by a team of researchers led by Dr. Andras Nagy at the Samuel Lunenfeld Research Institute of Mount Sinai Hospital and Dr. Lawrence Smith at the University of Montreal's Faculty of Veterinary Science.

28 Feb 2011

Final data from 4SC vidofludimus ENTRANCE Phase IIa trial against IBD presented at ECCO IBD Conference

4SC AG, a drug discovery and development company focused on autoimmune and cancer indications, announces the final data from the ENTRANCE Phase IIa trial in inflammatory bowel disease with vidofludimus, an oral inhibitor of interleukin-17 release and DHODH, including the secondary endpoints comprising the analysis of CDAI and CAI disease scores, change of prednisolone intake and threshold doses, safety, pharmacokinetics and biomarkers.

28 Feb 2011

Pharming, Santarus receive FDA refusal to file letter for RHUCIN BLA

Specialty biopharmaceutical company Santarus, Inc.and biotech company Pharming Group NV today announced the receipt of a "refusal to file" letter from the U.S. Food and Drug Administration for the RHUCIN Biologics License Application submitted by Pharming.

28 Feb 2011

Protalix receives FDA CRL for taliglucerase alfa NDA for Gaucher disease

Protalix BioTherapeutics, Inc., announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding the Company's New Drug Application (NDA) for taliglucerase alfa for the treatment of Gaucher disease. Taliglucerase alfa is a plant-cell expressed form of glucocerebrosidase (GCD).

25 Feb 2011

Research sheds new light on problem of insulin resistance in type 2 diabetes

A research team, led by La Jolla Institute scientist Joel Linden, Ph.D., has shed new light on the problem of insulin resistance, and identified the key participants in a molecular pathway that holds therapeutic promise for reducing the severity of type 2 diabetes.

25 Feb 2011

More than one way to silence gene activity

There's more than one way to silence gene activity, according to a Michigan State University researcher.

25 Feb 2011

The Lancet journal publishes XGEVA Phase 3 study results against prostate cancer, bone metastases

Amgen today announced the publication of results from a Phase 3 head-to-head trial that compared XGEVA to Zometa in preventing bone complications called skeletal-related events in 1,901 men with prostate cancer and bone metastases.

25 Feb 2011

Isis Pharma announces ISIS-CRPRx Phase 1 trial results in diseases with elevated CRP

Isis Pharmaceuticals, Inc. announced today the results from a Phase 1 clinical trial in which ISIS-CRPRx produced statistically significant reductions in C-reactive protein in the cohort of subjects in the study with elevated CRP.

24 Feb 2011

Bunion deformity more frequent in women, greatly reduces general, foot-specific HRQOL

New research determined that an increase in the severity of hallux valgus, or bunion deformity, progressively reduced both general and foot-specific health related quality of life. Bunion deformity was found in 36% of the study population and occurred more frequently in women and older individuals. Pain in other parts of the body beyond the foot was associated with increased bunion severity.

24 Feb 2011

Prevalence of bunions increases with age; More common in women

New research determined that an increase in the severity of hallux valgus, or bunion deformity, progressively reduced both general and foot-specific health related quality of life (HRQOL). Bunion deformity was found in 36% of the study population and occurred more frequently in women and older individuals.

23 Feb 2011

Amgen announces publication of XGEVA Phase 3 study results against solid tumors in Journal of Clinical Oncology

Amgen today announced the publication of results from a pivotal Phase 3 study of 1,776 advanced cancer patients with different types of solid tumors or multiple myeloma, which compared XGEVA to Zometa in preventing skeletal-related events.

23 Feb 2011

Regeneron submits VEGF Trap-Eye BLA to FDA for treatment of wet AMD

Regeneron Pharmaceuticals, Inc. announced that the company submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration (wet AMD). Under the Prescription Drug User Fee Act (PDUFA), the goal for a standard review time from submission to FDA action is ten months.

22 Feb 2011

New Harris Poll suggests that many doctors dont help obese patients to lose weight

A new Harris Poll suggests that many doctors are doing little or nothing to help their overweight patients to lose weight.

22 Feb 2011

Pharming, Santarus begin RHUCIN Phase IIIb study in patients with Hereditary Angioedema

Specialty biopharmaceutical company Santarus, Inc. and biotech company Pharming Group NV (NYSE Euronext: PHARM) today announced that Pharming has begun an international, multicenter, randomized, placebo-controlled Phase IIIb clinical study evaluating the investigational drug RHUCIN for the treatment of acute attacks of angioedema in patients with Hereditary Angioedema.

22 Feb 2011

Arthritis News and Research

Latest Arthritis News and Research

'Prehabilitation' exercise program can improve strength, functional ability before knee replacement surgery

Leptin receptor antagonist peptide demonstrates efficacy against triple negative breast cancer

Daiichi Sankyo enters merger agreement to acquire Plexxikon

Regeneron's ARCALYST meets primary, secondary endpoints in second Phase 3 gout flare study

Exactech fourth quarter total revenue increases 7% to $51.8 million

SQI Diagnostics first quarter net loss increases to $2,255,000

New horse stem cell discovery aids in preclinical model development for human degenerative diseases

Final data from 4SC vidofludimus ENTRANCE Phase IIa trial against IBD presented at ECCO IBD Conference

Pharming, Santarus receive FDA refusal to file letter for RHUCIN BLA

Protalix receives FDA CRL for taliglucerase alfa NDA for Gaucher disease

Research sheds new light on problem of insulin resistance in type 2 diabetes

More than one way to silence gene activity

The Lancet journal publishes XGEVA Phase 3 study results against prostate cancer, bone metastases

Isis Pharma announces ISIS-CRPRx Phase 1 trial results in diseases with elevated CRP

Bunion deformity more frequent in women, greatly reduces general, foot-specific HRQOL

Prevalence of bunions increases with age; More common in women

Amgen announces publication of XGEVA Phase 3 study results against solid tumors in Journal of Clinical Oncology

Regeneron submits VEGF Trap-Eye BLA to FDA for treatment of wet AMD

New Harris Poll suggests that many doctors dont help obese patients to lose weight

Pharming, Santarus begin RHUCIN Phase IIIb study in patients with Hereditary Angioedema

Exploring the role of confocal-based high-content imaging in advancing core facilities

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Arthritis News and Research

Latest Arthritis News and Research

Exploring the role of confocal-based high-content imaging in advancing core facilities

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Newsletters you may be interested in